Dasiglucagon Under Review for Severe Hypoglycemia
The FDA has accepted for review the New Drug Application for dasiglucagon HypoPal® Rescue Pen (Zealand Pharma) for the treatment of severe hypoglycemia.
Hypoglycemia
Nonglycemic Factors Increase Risk for Peripheral Neuropathy in T1D
Several nonglycemic factors may increase the risk for the development of diabetic peripheral neuropathy (DPN) among people with type 1 diabetes.
Solution-Stable Glucagon Granted Orphan Drug Status for Congenital Hyperinsulinism
The FDA has granted Orphan Drug designation to ABG-023, a glucagon analog (AmideBio), for the treatment of congenital hyperinsulinism.
Dasiglucagon NDA for Severe Hypoglycemia Treatment Submitted to FDA
The submission is supported by three phase 3 trials in adult and pediatric patients that showed dasiglucagon met the primary and all key secondary end points.
Glucagon Emergency Kit Now Available for Severe Hypoglycemia
Fresenius Kabi announced the launch of Glucagon Emergency Kit for the treatment of severe hypoglycemic episodes in adult and pediatric patients with diabetes.
Severe Hypoglycemia Linked to Worse Cognition in Older Patients With T1D
Both recent severe hypoglycemia (SH) and lifetime SH are associated with worse cognition among older adults with type 1 diabetes.
Intermittently Scanned CGM May Reduce Hypoglycemia in T1D
Intermittently scanned continuous glucose monitoring results in higher treatment satisfaction among adults with type 1 diabetes.
Endocrine Society Releases Hypoglycemia Performance Measures for Older Adults
A new set of quality measures can help health care providers identify older adults with type 2 diabetes who are at increased risk for hypoglycemia.
Hypoglycemia Risk May Be Lower With Liver-Targeted Rapid-Acting Insulin Formulation
Hepatic-directed vesicle insulin, a novel liver-targeted rapid-acting insulin formulation for type 1 diabetes, is noninferior to insulin lispro for improvement of HbA1c and is associated with a lower hypoglycemia risk in some patients.
Ready-to-Use Liquid Glucagon Receives Approval for Severe Hypoglycemia
The Food and Drug Administration (FDA) has approved Gvoke (glucagon; Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.
- Loading...
Loading...
Next post in Diabetes
Loading... 
Loading...